PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Media
Touchlight wins CPHI Pharma Award for cell-free DNA manufacturing

Touchlight wins CPHI Pharma Award for cell-free DNA manufacturing

The UK biotech's Doggybone DNA platform won the Innovation Catalyst category at CPHI Milan 2026, recognising its potential to support scalable DNA production for genetic medicines
Manufacturing
Xelia and Hisun sign strategic global multiple-API partnership

Xelia and Hisun sign strategic global multiple-API partnership

Long-standing joint venture partners expand collaboration, moving beyond anti-infective APIs into diversified therapeutic areas, including cardiovascular and oncology
Regulatory
ASA bans first weight loss pill ads

ASA bans first weight loss pill ads

The UK's advertising watchdog has ruled against several companies advertising oral GLP-1 weight loss medications to the UK public, working with the MHRA to ensure compliance and "protect the public"
Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Regulatory
Why early notified-body engagement matters for combination product success (VIDEO)

Why early notified-body engagement matters for combination product success (VIDEO)

Learn why early notified-body engagement is critical for combination products, including design rationale, risk controls, validation evidence and traceable documentation ahead of submission.
Finance
Piramal Pharma receives Ontario investment for API site

Piramal Pharma receives Ontario investment for API site

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the Ontario government
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Subscribe now